Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.

BMC cancer - 27 Jun 2018

Glassman Danielle C, Palmaira Randze L, Covington Christina M, Desai Avni M, Ku Geoffrey Y, Li Jia, Harding James J, Varghese Anna M, O'Reilly Eileen M, Yu Kenneth H

Abstract excerpt

BACKGROUND: Effective treatment options for advanced pancreatic cancer are finite. NAPOLI-1, a phase III randomized trial, demonstrated the efficacy of nanoliposomal irinotecan with fluorouracil/leucovorin (nal-IRI + 5-FU/LV) for the treatment of advanced pancreatic cancer following progression on gemcitabine-based chemotherapy. There are limited additional data on the safety and efficacy of nal-IRI + 5-FU/LV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Irinotecan

Share to Liposomes

Share to Nanoparticles

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 29945562
DOI: 10.1186/s12885-018-4605-1
PMCID: PMC6020418

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.PMID 29945562Read ↗

Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxelSemantic proximity Read ↗

Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy.Semantic proximity Read ↗

Current and future therapies for advanced pancreatic cancer.Semantic proximity Read ↗

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.Semantic proximity Read ↗

Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer.Semantic proximity Read ↗

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.Semantic proximity Read ↗

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial.Semantic proximity Read ↗

A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid TumorsSemantic proximity Read ↗

Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?Semantic proximity Read ↗

Exploring prognostic survival factors in patients with advanced pancreatic cancer receiving PD-1 inhibitorsSemantic proximity Read ↗

Safety of Endostar in combination with chemotherapy in patients with cancerSemantic proximity Read ↗

Intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial (METAPANC)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.